^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    enoxaparin sodium

    i
    Other names: PK 10169, PRY 005, RP 54563, RPY 005
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    Factor Xa inhibitor
    Associations

    News

    Trials
    24d
    A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR2600116304)
    P=N/A, N=338, Not yet recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    nafamostat • enoxaparin sodium
    24d
    Prevention of Venous Thromboembolism in Patients with Intracerebral Hemorrhage (POWER) (ChiCTR2500113625)
    P=N/A, N=600, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University
    New trial
    |
    enoxaparin sodium
    26d
    CARE: Comparison of Apixaban Versus Enoxaparin (clinicaltrials.gov)
    P=N/A, N=90, Enrolling by invitation, Abramson Cancer Center at Penn Medicine | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    enoxaparin sodium
    28d
    A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (clinicaltrials.gov)
    P1, N=186, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enoxaparin sodium
    1m
    A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (clinicaltrials.gov)
    P2, N=450, Recruiting, Sirius Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enoxaparin sodium
    2ms
    A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (clinicaltrials.gov)
    P1, N=186, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    enoxaparin sodium
    3ms
    HEM-DOAC: Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Medical University of Gdansk
    New trial
    |
    enoxaparin sodium
    3ms
    Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty (clinicaltrials.gov)
    P2, N=64, Terminated, Shanghai Hengrui Pharmaceutical Co., Ltd. | N=500 --> 64 | Recruiting --> Terminated; Adjustment of the sponsor's R&D strategy
    Enrollment change • Trial termination
    |
    enoxaparin sodium
    3ms
    HIPSTER-Pilot: Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (clinicaltrials.gov)
    P3, N=100, Not yet recruiting, McMaster University
    New P3 trial
    |
    Fragmin (dalteparin sodium) • aspirin • enoxaparin sodium
    4ms
    Severe acute respiratory syndrome coronavirus 2 infection and West Nile encephalitis in a patient with chronic kidney disease. (PubMed, J Crit Care Med (Targu Mures))
    On the second day of admission, the patient tested positive for COVID-19 and she was commenced on therapy with remdesivir, ceftriaxone, dexamethasone, and clexane. After 15 days of hospitalization, the patient was discharged in good clinical condition, except for mild tremor in her limbs. Periodic epidemic bursts of WNV infection have been reported in Mures County, but present coinfection is rare; the severity and prognosis of the disease are unforeseeable.
    Journal
    |
    CRP (C-reactive protein)
    |
    dexamethasone • enoxaparin sodium
    4ms
    Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH) (clinicaltrials.gov)
    P4, N=12, Recruiting, University of California, Irvine | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    enoxaparin sodium
    4ms
    EPOS: Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites. (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial
    |
    enoxaparin sodium